Merck Bets Big on Cancer Treatment with $2.13B KRAS Deal
Merck has acquired exclusive global rights to SPR2015, an oral KRAS G12D inhibitor, from SciBrunch Therapeutics for $2.13 billion. The agreement covers SPR2015 at the preclinical stage and adds a targeted oncology candidate focused on the KRAS G12D mutation. Merck described the deal as a multi-billion dollar commitment aimed at expanding its future oncology pipeline.
The move to license SPR2015 tells only part of the story for how Merck's wider cancer strategy could evolve. To build more than 20 new growth drivers before Keytruda's exclusivity loss becomes a bigger issue, management is paying $400 million upfront, with up to $2.13 billion in potential total value.
The deal fits squarely into Merck's efforts to deepen targeted cancer treatments within its broad oncology portfolio. To see SPR2015 enter and progress through formal clinical trials, with initial safety and efficacy readouts that justify Merck's multi-billion dollar commitment, is the next proof point for investors.